These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37672605)

  • 21. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.
    Weisler RH; Pandina GJ; Daly EJ; Cooper K; Gassmann-Mayer C;
    CNS Drugs; 2012 May; 26(5):421-34. PubMed ID: 22519922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Phase 3, Randomized Double-Blind Study of the Efficacy and Safety of Low-Dose SHP465 Mixed Amphetamine Salts Extended-Release in Children with Attention-Deficit/Hyperactivity Disorder.
    Mattingly G; Arnold V; Yan B; Yu M; Robertson B
    J Child Adolesc Psychopharmacol; 2020 Nov; 30(9):549-557. PubMed ID: 33185468
    [No Abstract]   [Full Text] [Related]  

  • 23. Parent training interventions for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 5 to 18 years.
    Zwi M; Jones H; Thorgaard C; York A; Dennis JA
    Cochrane Database Syst Rev; 2011 Dec; 2011(12):CD003018. PubMed ID: 22161373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Homeopathic medicinal products for preventing and treating acute respiratory tract infections in children.
    Hawke K; King D; van Driel ML; McGuire TM
    Cochrane Database Syst Rev; 2022 Dec; 12(12):CD005974. PubMed ID: 36511520
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation.
    Swanson JM; Greenhill LL; Lopez FA; Sedillo A; Earl CQ; Jiang JG; Biederman J
    J Clin Psychiatry; 2006 Jan; 67(1):137-47. PubMed ID: 16426100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Wilens TE; Robertson B; Sikirica V; Harper L; Young JL; Bloomfield R; Lyne A; Rynkowski G; Cutler AJ
    J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):916-25.e2. PubMed ID: 26506582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of a Long-Acting Multilayer-Release Methylphenidate Formulation (PRC-063) in the Treatment of Adolescent Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Clinical Trial with a 6-Month Open-Label Extension.
    Weiss MD; Cutler AJ; Kollins SH; Donnelly GAE
    J Child Adolesc Psychopharmacol; 2021 Nov; 31(9):610-622. PubMed ID: 34637343
    [No Abstract]   [Full Text] [Related]  

  • 28. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
    Harfterkamp M; van de Loo-Neus G; Minderaa RB; van der Gaag RJ; Escobar R; Schacht A; Pamulapati S; Buitelaar JK; Hoekstra PJ
    J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):733-41. PubMed ID: 22721596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial.
    Wietecha L; Williams D; Shaywitz S; Shaywitz B; Hooper SR; Wigal SB; Dunn D; McBurnett K
    J Child Adolesc Psychopharmacol; 2013 Nov; 23(9):605-13. PubMed ID: 24206099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children.
    Nasser A; Liranso T; Adewole T; Fry N; Hull JT; Chowdhry F; Busse GD; Cutler AJ; Jones NJ; Findling RL; Schwabe S
    Clin Ther; 2020 Aug; 42(8):1452-1466. PubMed ID: 32723670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Results of a Randomized, Double-Blind Placebo-Controlled Study.
    Brams M; Childress AC; Greenbaum M; Yu M; Yan B; Jaffee M; Robertson B
    J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):19-28. PubMed ID: 28816509
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial.
    Connor DF; Findling RL; Kollins SH; Sallee F; López FA; Lyne A; Tremblay G
    CNS Drugs; 2010 Sep; 24(9):755-68. PubMed ID: 20806988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study.
    Weisler RH; Greenbaum M; Arnold V; Yu M; Yan B; Jaffee M; Robertson B
    CNS Drugs; 2017 Aug; 31(8):685-697. PubMed ID: 28712074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of methylphenidate and behavioural parent training for children aged 3-5 years with attention-deficit hyperactivity disorder: a randomised, double-blind, placebo-controlled, and sham behavioural parent training-controlled trial.
    Sugaya LS; Salum GA; de Sousa Gurgel W; de Morais EM; Del Prette G; Pilatti CD; Dalmaso BB; Leibenluft E; Rohde LA; Polanczyk GV
    Lancet Child Adolesc Health; 2022 Dec; 6(12):845-856. PubMed ID: 36306807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.
    Soutullo C; Banaschewski T; Lecendreux M; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Bloomfield R; Squires LA; Coghill DR
    CNS Drugs; 2013 Sep; 27(9):743-51. PubMed ID: 23801529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Clinical Trial of ORADUR-Methylphenidate for Treating Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Huang YS; Yeh CB; Chen CH; Shang CY; Gau SS
    J Child Adolesc Psychopharmacol; 2021 Apr; 31(3):164-178. PubMed ID: 33395356
    [No Abstract]   [Full Text] [Related]  

  • 37. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Epstein T; Patsopoulos NA; Weiser M
    Cochrane Database Syst Rev; 2014 Sep; (9):CD005041. PubMed ID: 25230710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
    Biederman J; Swanson JM; Wigal SB; Kratochvil CJ; Boellner SW; Earl CQ; Jiang J; Greenhill L
    Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Homeopathic Treatment of Overweight and Obesity in Pregnant Women With Mental Disorders: A Double-blind, Controlled Clinical Trial.
    Vilhena EC; Castilho EA
    Altern Ther Health Med; 2016 Oct; 22(S3):14-22. PubMed ID: 27866182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder.
    Montoya A; Hervas A; Cardo E; Artigas J; Mardomingo MJ; Alda JA; Gastaminza X; García-Polavieja MJ; Gilaberte I; Escobar R
    Curr Med Res Opin; 2009 Nov; 25(11):2745-54. PubMed ID: 19785510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.